Vascepa Negative Panel Vote Clouds Future For Other Cholesterol Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
A broader indication needs cardiovascular outcomes data, FDA’s advisory committee says, and the agency seems to agree that new cholesterol-lowering drugs need stronger endpoints.
You may also be interested in...
Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency Says Not Likely
Continued availability of Takeda’s febuxostat should be restricted to second-line use in gout patients who cannot tolerate or fail allopurinol, advisory committee majority says, opposing market withdrawal; but panelists’ suggestion that a Risk Evaluation and Mitigation Strategy be put in place to ensure patients and prescribers discuss cardiovascular risks receives pushback from agency.
Panel To Weigh Amarin’s Expanded Vascepa Use Given Clinical Outcome Concerns
FDA advisors will discuss Oct. 16 whether Vascepa’s effect on reducing triglycerides is enough to overcome concerns about this surrogate endpoint not panning out in other drug’s clinical outcomes trials.
HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers
While risks clearly outweigh benefits for niacin as an add-on therapy in the more than 25,000-patient HPS2-THRIVE study, investigators argue that the door is still open for other HDL-raising drugs. One panelist at the ACC meeting where results were presented calls for smaller, more targeted trials in the future.